Core Insights - The domestic fundamental and liquidity environment is expected to support the A-share market, with short-term influences from the Middle East situation and control over the Taiwan Strait [2][4] - The A-share market may face a decisive period in April, with potential recovery in earnings as the financial reporting window opens [2][4] - Investment opportunities in the new energy sector are highlighted, particularly in solar and wind power, which are less affected by geopolitical conflicts and fossil fuel prices [2][4] Real Estate Sector: Poly Real Estate Group - Poly Real Estate Group's sales ranking improved to 12th in January 2026, with a sales amount of 3.7 billion yuan, despite a year-on-year decline of 22.9% [8] - The company achieved a sales area of 150,000 square meters in January 2026, down 6.8% year-on-year, with an average sales price of 24,800 yuan per square meter, a decrease of 16.5% [8] - The company has a strong backing from its parent company, Poly Group, which holds 48.09% of its shares, providing stability and growth potential [11] Transportation Sector: COSCO Shipping Specialized Carriers - COSCO Shipping Specialized Carriers reported a revenue of 16.611 billion yuan in the first three quarters of 2025, a year-on-year increase of 37.92% [13] - The company’s net profit reached 1.329 billion yuan, up 10.54% year-on-year, with a significant increase in cash flow from operating activities [13] - The expansion of the fleet and increased shipping business revenue are key drivers of growth, despite rising operational costs [13][14] Transportation Sector: Jitu Express - Jitu Express achieved a total revenue of 5.499 billion USD in the first half of 2025, a year-on-year increase of 13.1%, with significant growth in the Southeast Asian market [15][16] - The company’s Southeast Asian market revenue grew by 29.6%, reaching 1.970 billion USD, with an adjusted EBITDA of 313 million USD [15][16] - The company is focusing on cost optimization and pricing strategies to enhance market share in a competitive environment [17] Chemical Sector: Satellite Chemical - Satellite Chemical reported a gross margin of 22.31% in 2025, with a net margin of 11.52%, despite a slight decline in both metrics [18] - The company’s asset-liability ratio decreased to 51.74%, indicating improved financial stability [18] - The company plans to distribute a cash dividend of 1.678 billion yuan, reflecting a commitment to shareholder returns [18] Chemical Sector: Yake Technology - Yake Technology's revenue grew significantly due to increased sales in LNG and electronic materials, although net profit growth lagged behind revenue growth due to foreign exchange losses [21][22] - The company is focusing on developing advanced semiconductor materials and has established a dual R&D department in China and South Korea [22] - The company’s gross margin was 31.82%, with a net margin of 13.29%, indicating stable profitability despite rising R&D costs [21] New Energy Sector: CATL - CATL reported a revenue of 423.702 billion yuan in 2025, a year-on-year increase of 17.04%, with a net profit growth of 42.28% [25] - The company maintained its leading position in the global battery market, achieving a market share of 39.2% in 2025 [25][26] - CATL's energy storage battery sales grew by 29.13%, with ongoing expansion of production capacity to meet market demand [26] Pharmaceutical Sector: Tasly Pharmaceutical - Tasly Pharmaceutical's revenue was 8.236 billion yuan in 2025, a slight decline of 3.08%, with core products showing stable sales [27][28] - The company is focusing on innovation and has a robust pipeline of new drug projects, with significant R&D investment [29] - The integration with China Resources has strengthened the company's market position and operational efficiency [27] Food and Beverage Sector: Kweichow Moutai - Kweichow Moutai's revenue for Q3 2025 was 39.06 billion yuan, with a slight year-on-year increase of 0.6%, indicating a strategic adjustment in growth [33] - The company is focusing on maintaining quality and long-term value, with plans for internationalization and brand enhancement [32][33] - The company announced a cash dividend of 23.957 yuan per share, reflecting its commitment to shareholder returns [33] Staffing Sector: Core International - Core International expects a steady increase in revenue and net profit in 2025, driven by technological advancements and operational efficiency [35] - The company is leveraging its data and technology capabilities to enhance its service offerings and market presence [35] - The integration of various business lines is expected to drive growth and improve profitability [35] Electronics Sector: Haixing Co., Ltd. - Haixing Co., Ltd. is positioned to benefit from the growing demand for AI server capacitors, with a projected market size increase in the coming years [37][38] - The company is enhancing its production capabilities to meet the rising demand for high-end aluminum electrolytic capacitors [38] - The company holds a leading market share in the aluminum foil sector, with ongoing improvements in technology and production processes [37]

股票代码：600535 股票简称：天士力 公告编号：临 2026-012 号 天士力医药集团股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，天士力医药集团股份有限公司（以下简称"公司"）全资子公司江苏 天士力帝益药业有限公司（以下简称"江苏帝益"）收到国家药品监督管理局核 准签发的米诺地尔搽剂《药品注册证书》，现就相关情况公告如下： 一、基本情况 药品名称：米诺地尔搽剂 剂型：搽剂 规格：2%（60 毫升：1.2 克）、5%（60 毫升：3.0 克） 注册分类：化学药品 3 类 证书编号：2026S00824、2026S00825 药品批准文号：国药准字 H20263690、国药准字 H20263691 上市许可持有人：江苏天士力帝益药业有限公司 生产企业：河南天地药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的相关情况 米诺地尔搽剂原研药最早于 1988 年 8 月在美国 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][5] Core Views - The company achieved a revenue of 8.236 billion yuan in 2025, a year-on-year decrease of 3.08%, while the net profit attributable to the parent company was 1.105 billion yuan, an increase of 15.63% [5] - The company maintains a strong gross margin of 66.85% and a net margin of 12.89% in 2025, indicating solid profitability despite revenue decline [5] - The company is focused on innovation and aims to double its industrial revenue by the end of 2030, targeting 15 billion yuan, through a strategic plan that emphasizes high clinical value products [7] Financial Summary - Revenue and Profit Forecasts: - 2026E revenue is projected at 8.646 billion yuan, with a year-on-year growth of 5.0% [8] - Net profit for 2026E is expected to be 1.265 billion yuan, reflecting a year-on-year increase of 14.5% [8] - Key Financial Ratios: - Gross margin is expected to remain stable around 66.9% for 2026E [11] - Net margin is projected to improve to 14.6% in 2026E [11] - Earnings per share (EPS) is forecasted to be 0.85 yuan for 2026E [8] Product Segment Performance - The cardiovascular and metabolic segment generated revenue of 4.067 billion yuan in 2025, a decrease of 1.80% [6] - The digestive segment led growth with a revenue increase of 3.91%, reaching 0.986 billion yuan [6] - The pharmaceutical commercial segment saw a significant decline in revenue, down 14.40% to 0.766 billion yuan [6]

Core Insights - The report highlights the investment opportunities in the pharmaceutical sector, particularly focusing on Tianjin Tianshi Co., Ltd. after the acquisition by China Resources Group, which is expected to drive long-term growth [5][6][9] - The report emphasizes the structural bull market trend in the A-share market, with a focus on the rising opportunities in the new energy sector due to elevated oil prices [11][12][13] - The transportation sector is experiencing shifts due to geopolitical tensions, with shipping routes being adjusted and new business models emerging in low-altitude economy and autonomous driving [21][22] Pharmaceutical Sector - Tianjin Tianshi reported a revenue of 8.236 billion yuan in 2025, a decrease of 3.08% year-on-year, while net profit attributable to shareholders was 1.105 billion yuan, an increase of 15.63% [5][6] - The company is focusing on innovation and has a robust pipeline with 31 projects under development, including 11 in cardiovascular and metabolic diseases [8] - The management has implemented a strategic plan aiming for a doubling of industrial revenue to 15 billion yuan by 2030, leveraging resources from China Resources [6][9] Energy Sector - The report notes that Brent crude oil prices have remained above $100, influenced by geopolitical conflicts, which underscores the importance of energy transition [13] - The new energy sector, including solar and wind power, is expected to perform well as it is less affected by geopolitical tensions compared to fossil fuels [13] - Investment opportunities in the new energy sector are highlighted, with various segments such as batteries and storage systems showing promising growth [13] Transportation Sector - The report discusses the impact of the geopolitical situation on shipping routes, with VLCCs rerouting to avoid disruptions in the Strait of Hormuz [21][22] - Air cargo capacity remains tight due to Middle Eastern tensions, leading to adjustments in flight schedules and routes by carriers [21][22] - The emergence of new business models in the low-altitude economy, including partnerships between tech companies and ride-sharing platforms, is noted as a significant trend [21][22]

股票代码：600535 股票简称：天士力 公告编号：临 2026-010 号 天士力医药集团股份有限公司 关于公司 2026 年度担保预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称：天津天士力医药商业有限公司（以下简称"天士力商业"）， 为公司的全资子公司，江苏鸿泰药业有限公司（以下简称"江苏鸿泰"），为公 司的全资孙公司。 本次担保金额及已实际为其提供的担保余额：天士力医药集团股份有限公 司（以下简称"公司"或"天士力"）为天士力商业不超过4.00亿元的银行融资 授信业务提供连带责任担保，为江苏鸿泰不超过4.00亿元的银行融资授信业务提 供连带责任担保，累计占公司最近一期经审计净资产的6.45%；公司对天士力商 业和江苏鸿泰提供的担保余额为人民币8.00亿元，占公司最近一期经审计净资产 的6.45%；无逾期担保事项。 本次担保是否有反担保：无。 对外担保逾期的累计数量：无。 一、担保情况概述 （一）担保基本情况 (一)天津天士力医药商业有限公司 | 企业名称 | 天津天士力医药商业有 ...

证券代码：600535 证券简称：天士力 公告编号：临2026-011 号 天士力医药集团股份有限公司 关于召开2025年年度股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 （一）股东会类型和届次 2025年年度股东会 （二）股东会召集人：董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2026 年 4 月 17 日 15 点 30 分 召开地点：天津市北辰科技园区天士力现代中药城天士力医药集团股份有限公 司会议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 4 月 17 日 至2026 年 4 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东 会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票 平台的投票时间为 ...

股票代码：600535 股票简称：天士力 公告编号：临 2026-009 号 天士力医药集团股份有限公司 第九届董事会第 19 次会议决议公告 表决情况为：有效表决票 15 票，其中：同意 15 票，反对 0 票，弃权 0 票。 本议案尚需提交公司 2025 年年度股东会审议。 二、关于召开 2025 年年度股东会的通知 内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的《关于召开 2025 年年度股东会的通知》（公告编号：临 2026-011 号）。 特此公告。 天士力医药集团股份有限公司（以下简称"公司"）第九届董事会第 19 次会 议通知于 2026 年 3 月 20 日以书面方式发出，会议于 2026 年 3 月 23 日以通讯方 式召开，会议应到董事 15 人，实到 15 人。会议符合《公司法》和《公司章程》 的有关规定，会议合法、有效。经与会人员逐项审议，通过了以下议案： 一、关于公司 2026 年度担保预计的议案 被担保方均为公司全资子/孙公司，本次担保计划事项是为满足天津天士力医 药商业有限公司、江苏鸿泰药业有限公司两家公司 2026 年度生产经营需要，有利 于提高融资效率 ...

Group 1 - The core viewpoint of the article emphasizes the potential for significant long-term growth in specific segments of the AI computing power investment landscape, despite short-term volatility in stock prices due to various factors [5] - The article highlights that the GTC conference and OFC conference have a synergistic effect, suggesting that the optical interconnection sector is likely to benefit from these developments [5] Group 2 - Ping An Bank reported a 10.4% decline in revenue and a 4.2% decrease in PPOP for 2025, with retail profit contribution showing signs of recovery [5] - CITIC Bank achieved a revenue of 212.5 billion, a slight decrease of 0.55%, but a net profit increase of 2.98%, with a dividend payout ratio rising to 31.75% [5] - Greentown Service's revenue reached 19.16 billion, up 7.1%, with a core operating profit increase of 24.6% and a dividend payout ratio of 75% [7] - Wanwu Cloud reported a revenue of 37.27 billion, a 2.7% increase, with a core net profit of 2.13 billion, reflecting a growth of 0.8% [7] - Wancheng Group achieved a revenue of 51.46 billion, a significant increase of 59.17%, and a net profit growth of 358.09% [7] - Tianshili's revenue was 8.236 billion, with a net profit of 1.105 billion, showing a 16% increase, despite a 3% decline in overall revenue [8]

Core Viewpoint - The company reported its 2025 annual results, showing a slight decline in revenue but a significant increase in net profit, primarily due to the appreciation of financial assets [4][5]. Financial Performance - In 2025, the company achieved operating revenue of 8.236 billion, a year-on-year decrease of 3.08%, while net profit attributable to shareholders rose by 15.63% to 1.105 billion [4]. - The company's cash flow from operating activities was 1.425 billion, down 29.28% year-on-year [4]. - The basic earnings per share (EPS) for 2025 was 0.74 yuan [4]. Industry Analysis - The pharmaceutical industry revenue remained stable, with the company's pharmaceutical manufacturing and commercial revenue at 7.382 billion and 766 million, respectively, reflecting declines of 2.54% and 14.40% [5]. - The decline in revenue was attributed to price reductions from centralized procurement and challenges in the traditional Chinese medicine injection market [5]. Profitability Metrics - The company's gross margin decreased by 0.29 percentage points to 66.85%, with pharmaceutical manufacturing and commercial gross margins at 70.37% and 31.85%, respectively [6]. - The decline in gross margin was linked to price reductions for specific products, such as the compound Danshen dripping pill [6]. - The company maintained a stable expense ratio, with total expenses decreasing by 0.52 percentage points to 48.18% [6]. Innovation and Strategic Planning - The company is committed to innovation in traditional Chinese medicine and advanced therapeutic drugs, focusing on cardiovascular, metabolic, neurological, and digestive fields [7]. - As of now, the company has 31 innovative drugs in development, with 4 in NDA/Pre NDA stages and 17 in clinical phases II and III [7]. - The company aims to double its industrial revenue to 15 billion by the end of 2030, reflecting strong confidence in its development strategy [8].

Investment Rating - The investment rating for the company is "Buy" with a market price of RMB 14.15, and the sector rating is "Outperform" compared to the market [2][4]. Core Views - The report highlights that with the entry of China Resources Group as the controlling shareholder, the company is undergoing a significant transformation, leading to improved governance and strategic upgrades. The approval of innovative traditional Chinese medicine products is expected to drive performance recovery and open long-term growth potential [4][6]. - The company reported a revenue of RMB 8.236 billion for 2025, a decrease of 3.08% year-on-year, while the net profit attributable to shareholders was RMB 1.105 billion, an increase of 15.63% year-on-year. The report anticipates a net profit of RMB 1.277 billion for 2026, reflecting a growth rate of 15.6% [4][6]. Summary by Sections Financial Performance - In 2025, the company achieved a revenue of RMB 82.36 billion, with a decline of 3.08% year-on-year. The net profit attributable to shareholders was RMB 11.05 billion, up 15.63% year-on-year. The fourth quarter of 2025 saw revenues of RMB 19.26 billion, down 5.39% year-on-year, and a net profit of RMB 1.21 billion, up 6.35% year-on-year [4][6]. - The report projects the company's net profit for 2026-2028 to be RMB 12.77 billion, RMB 14.04 billion, and RMB 15.73 billion, respectively, with corresponding EPS of RMB 0.85, RMB 0.94, and RMB 1.05 [6][8]. Market Position and Strategy - The company is focusing on enhancing its core business and expanding its innovative product pipeline, which is expected to contribute to stable growth in performance. The report emphasizes the importance of the collaboration with China Resources in optimizing sales expenses and improving management efficiency [4][6][9]. - The company aims to double its industrial revenue to RMB 15 billion by 2030, positioning itself among the top tier of pharmaceutical companies in China. The integration of resources and strategic planning with China Resources is expected to provide long-term growth momentum [9]. Research and Development - The company has increased its R&D investment to RMB 8.45 billion in 2025, accounting for 11.45% of its pharmaceutical industrial revenue. There are currently 31 innovative drug projects under development, with several in advanced clinical stages [9][10]. - The report notes that the company is focusing on cardiovascular and metabolic diseases, with multiple innovative drugs in various clinical trial phases. The successful approval of new products is anticipated to enhance market share and revenue [9][10].